[go: up one dir, main page]

EP0673559A1 - Systeme de moteur a tolerance de pannes - Google Patents

Systeme de moteur a tolerance de pannes

Info

Publication number
EP0673559A1
EP0673559A1 EP94903543A EP94903543A EP0673559A1 EP 0673559 A1 EP0673559 A1 EP 0673559A1 EP 94903543 A EP94903543 A EP 94903543A EP 94903543 A EP94903543 A EP 94903543A EP 0673559 A1 EP0673559 A1 EP 0673559A1
Authority
EP
European Patent Office
Prior art keywords
windings
motor
winding
synchronized
control means
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94903543A
Other languages
German (de)
English (en)
Inventor
Robert H. Hoel
Zygmut Zubkow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Honeywell Inc
Original Assignee
Honeywell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Honeywell Inc filed Critical Honeywell Inc
Publication of EP0673559A1 publication Critical patent/EP0673559A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02K—DYNAMO-ELECTRIC MACHINES
    • H02K16/00—Machines with more than one rotor or stator
    • H02K16/04—Machines with one rotor and two stators
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02K—DYNAMO-ELECTRIC MACHINES
    • H02K29/00—Motors or generators having non-mechanical commutating devices, e.g. discharge tubes or semiconductor devices
    • H02K29/06—Motors or generators having non-mechanical commutating devices, e.g. discharge tubes or semiconductor devices with position sensing devices

Definitions

  • This invention relates generally to brushless DC motor systems.
  • the invention relates to a brushless DC motor system especially adapted for use in high reliability uses where redundancy is essential, such as in thrust vector control of rocket engines.
  • Thrust vector control of rocket engines has in the past been primarily accomplished with the use of hydraulic actuators.
  • Hydraulic actuators employing hydraulic pumps while commonly in use, have a disadvantage in that they require high- maintenance costs and suffer from low reliability. More particularly, hydraulic pumps typically run at full speed thereby requiring operation of the hydraulic system controlling the rocket engine to operate at continuous maximum power. Other disadvantages include the fact that they require use of dangerous materials such as hydrazine and are generally very messy due to the presence of hydraulic fluid over the parts.
  • Alternative approaches to hydraulic actuators have involved the use of electromagnetic actuators. In comparison to hydraulic systems, electromagnetic actuator systems use much less energy, with a typical hydraulic actuator system using over 34 times as much energy during a mission as a comparable electromagnetic actuator system.
  • DC brushless motors are available in several configurations from open loop controlled multi-toothed propelled drives called stepping motors to inside permanent magnet rotor and outside permanent magnet rotor closed loop machines. Due to their wide range of performance and motion control capabilities, such motors are theoretically particularly desirable for use in applications such as rocket vector control, for example, in controlling the direction of orientation of rocket motor nozzles. However, such motors have not been used widely in the field of rocket nozzle control because in the event of shorting of the winding of the motor, the system could experience a catastrophic failure due to the inability to move the DC brushless motor, which locks up upon the shorting of a winding. As may be appreciated, such a failure in the motor can result in a complete and catastrophic failure of the rocket mission.
  • the permanent magnet motor system includes a shaft for having multiple permanent magnets mounted thereon, and with the shaft rotatably mounted for rotation about a central axis thereof.
  • the permanent magnets are mounted along a predetermined length of the shaft, substantially around the circumference thereof, for causing the shaft to rotate as a result of an inductive force being applied to the permanent magnets.
  • At least three windings, each electrically isolated from each other, are arranged around the permanent magnets, each for being individually electrically excited to generate an induction field. The field generated causes the shaft to rotate as a result of the interaction between the generated field and the permanent magnets.
  • Individual winding controllers for example, pulse width modulation controller chips, individually control each of the windings in a manner such that should there be a short in one of the windings, the other two windings continue to generate the necessary fields to (1) continue to drive the shaft in a rotational motion, and (2) overcome the drag created by the shorted winding.
  • the motor system is fault tolerant taking into account, in a DC brushless motor arrangement, the possible shorting of a winding thereof.
  • the windings are preferably arranged in a Y-winding configuration with each of the winding legs parallel to the others. Such a configuration is conventional and well known to those of ordinary skill in the art.
  • the winding controllers are insulated gate bipolar transistor power modules.
  • the windings comprise at least three windings and more preferably, at least eight. As may be appreciated, in the case with eight windings, should one winding short, the motor will still retain 3/4 of its power due to the loss of one winding by shorting, and another winding being dedicated to overcoming the drag of the winding that shorted. In the case of a single winding shorting in a three winding arrangement, 1/3 power is retained.
  • a sensor or sensors are arranged for detecting the rotational position of the shaft.
  • the sensor or sensors provide a signal to a motor controller, which controls the insulated gate bipolar transistor power modules of the windings, to issue a control signal to the power modules to excite the windings to cause the shaft to be rotated into a desired position.
  • Figure 1 is a schematic diagram of the control circuit architecture and winding arrangement for a DC brushless motor system in accordance with the invention.
  • Figure 2 is a second schematic diagram showing the control modules of Figure 1 connected to a motor controller, and with the motor shaft having a position sensor thereon.
  • the fault tolerant winding control system in accordance with the invention, is designated generally by the reference number 1 1.
  • a single common shaft 13 is shown illustrated in association with redundant windings 17 arranged in a Y configuration about the shaft.
  • the shaft 13 includes permanent magnets
  • the windings 17 are connected in a manner to be individually and separately electrically excited to generate a field which interacts with the magnets to cause the shaft 13 to rotate.
  • Each winding 17 has three legs, 19a, 19b, and 19c, which are arranged in a conventional and well known Y configuration.
  • each winding 17 is shown individually controlled by a respective control module 21.
  • These modules 21 are, for example, insulated gate bipolar transistor power modules.
  • the other redundant windings 17, which are each individually and separately controlled by the power modules 21 through insulated gate bipolar transistors 23a, 23b and 23c, continue to drive the shaft 13 of the motor.
  • modules 21 they are conventional and well known to those of ordinary skill in the art. Examples of such commercially available modules include the PWR-82331 high current three-phase bridge power hybrid. Details of such a module are disclosed in the publication by ILC Data Device Corporation PWR-282331 Smart Power Three-Phase Bridge. 1989, which disclosure is incorporated by reference herein.
  • a motor controller 27 is employed to control the power modules 21 such that they are synchronized to ensure that the magnets are acted upon by the fields generated by individual windings 17 in a synchronized manner.
  • a motor controller 27 is employed.
  • Such a controller 27 is conventional and well known and can take the form of, for example, a programmable logic array (PLA).
  • PPA programmable logic array
  • position sensors 29 can be mounted on the shaft 13 to detect the position of the shaft 13 relative to where it has been commanded by motor controller 27 to be located.
  • the position detection sensors 29 provide a position signal to motor controller 27 wherein it is compared to a reference to result in an error signal.
  • the error signal is then processed by the controller 27 to generate a signal to the control modules 21 to cause the shaft 19 to be rotated to the desired position correcting for the error until the error signal generated is equal to null.

Landscapes

  • Engineering & Computer Science (AREA)
  • Power Engineering (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Permanent Magnet Type Synchronous Machine (AREA)
  • Brushless Motors (AREA)

Abstract

Moteur c.c. sans balais qui comporte une pluralité de bobinages (17) parallèles, chacun étant commandé individuellement par un module de commande respectif (21). Ces bobinages sont au nombre de trois au moins, de telle manière que s'il y a un court-circuit dans l'un deux, les deux autres bobinages continuent à générer un champ pour provoquer la rotation de l'arbre (13) du moteur sur lequel sont montés des aimants permanents (15). De préférence, les bobinages (17) sont au nombre de trois au moins si bien qu'en cas d'un seul court-circuit, l'un des deux bobinages restants sert à compenser la traînée engendrée par le bobinage qui a subi le court-circuit, l'autre bobinage restant générant un champ pour entraîner la rotation de l'arbre (13) du moteur. Ledit système de moteur a une application particulière dans le domaine de la commande vectorielle de tuyères de fusée. Dans un mode préféré de réalisation, le système comporte huit bobinages (17).
EP94903543A 1992-12-14 1993-12-09 Systeme de moteur a tolerance de pannes Withdrawn EP0673559A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99224292A 1992-12-14 1992-12-14
US992242 1992-12-14
PCT/US1993/011956 WO1994014226A1 (fr) 1992-12-14 1993-12-09 Systeme de moteur a tolerance de pannes

Publications (1)

Publication Number Publication Date
EP0673559A1 true EP0673559A1 (fr) 1995-09-27

Family

ID=25538089

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94903543A Withdrawn EP0673559A1 (fr) 1992-12-14 1993-12-09 Systeme de moteur a tolerance de pannes

Country Status (4)

Country Link
EP (1) EP0673559A1 (fr)
JP (1) JPH08504559A (fr)
RU (1) RU95114435A (fr)
WO (1) WO1994014226A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108945485A (zh) * 2017-05-17 2018-12-07 通用电气公司 用于飞行器的推进系统

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929549A (en) * 1998-04-02 1999-07-27 Pacific Scientific Company Fault tolerant electric machine
US6437529B1 (en) 1998-05-04 2002-08-20 Comair Rotron, Inc. Multi-stator motor with independent stator circuits
DE19856647B4 (de) * 1998-12-09 2007-03-01 Canders, Wolf-R., Prof. Dr.-Ing. Elektrischer Hochmomentmotor
EP1262687B1 (fr) * 2001-06-01 2009-03-25 IHI Aerospace Co., Ltd. Mécanisme de commande à moteur électrique et son procédé de commande
EP1296443B1 (fr) * 2001-09-19 2006-10-04 Parker Hannifin Corporation Entraîneur pour moteur et système
US6791209B2 (en) 2002-01-02 2004-09-14 Intel Corporation Power and control for power supply fans
US6819017B2 (en) 2002-01-02 2004-11-16 Intel Corporation Method and apparatus for fan redundancy
US6700266B2 (en) * 2002-01-02 2004-03-02 Intel Corporation Multiple fault redundant motor
US6724183B2 (en) 2002-01-02 2004-04-20 Intel Corporation Method and apparatus for detecting bearing failure
US7583063B2 (en) 2003-05-27 2009-09-01 Pratt & Whitney Canada Corp. Architecture for electric machine
WO2007136989A2 (fr) 2006-05-05 2007-11-29 Isis Pharmaceuticals, Inc. Composés et procédés pour moduler l'expression de dgat2
EP2505650A1 (fr) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Composés et procédé pour moduler lýexpression de PCSK9
US7443642B2 (en) 2006-05-26 2008-10-28 Pratt & Whitney Canada Corp. Electric motor control
GB0613941D0 (en) 2006-07-13 2006-08-23 Pml Flightlink Ltd Electronically controlled motors
JP5665317B2 (ja) 2006-10-18 2015-02-04 アイシス ファーマシューティカルズ， インコーポレーテッド アンチセンス化合物
US7541705B2 (en) 2007-03-28 2009-06-02 General Electric Company Fault-tolerant permanent magnet machine with reconfigurable flux paths in stator back iron
US7605504B2 (en) 2007-03-28 2009-10-20 General Electric Company Fault-tolerant permanent magnet machine with reconfigurable stator core slot flux paths
US7605503B2 (en) 2007-03-28 2009-10-20 General Electric Company Fault-tolerant permanent magnet machine with reconfigurable stator core slot opening and back iron flux paths
DE102007048642A1 (de) * 2007-10-10 2009-04-16 Mtu Aero Engines Gmbh Elektrischer Antrieb, insbesondere für eine Kraftstoffzumesseinheit für ein Flugzeugtriebwerk
CA2726052A1 (fr) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation de l'expression genique par ciblage d'un petit arn endogene de promoteurs de genes
CA2732343C (fr) 2008-07-29 2017-05-09 The Board Of Regents Of The University Of Texas System Inhibition selective d'expression de proteine de polyglutamine
WO2010048585A2 (fr) 2008-10-24 2010-04-29 Isis Pharmaceuticals, Inc. Composés oligomères et méthodes
US8476798B2 (en) 2008-11-28 2013-07-02 Pratt & Whitney Canada Corp. Tandem electric machine arrangement
US20120021515A1 (en) 2009-02-06 2012-01-26 Swayze Eric E Oligomeric compounds and methods
US8815586B2 (en) 2009-04-24 2014-08-26 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions
GB2462940B8 (en) * 2009-09-03 2012-03-28 Protean Holdings Corp Electric motor and electric generator.
US8749192B2 (en) 2009-09-03 2014-06-10 Protean Electric Limited Electric motor and electric generator
US20110110860A1 (en) 2009-11-02 2011-05-12 The Board Of Regents Of The University Of Texas System Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
CN106146591B (zh) 2010-01-08 2020-07-31 Ionis制药公司 血管生成素样3表达的调节
WO2011097388A1 (fr) 2010-02-03 2011-08-11 Alnylam Pharmaceuticals, Inc. Inhibition sélective de l'expression de la protéine de polyglutamine
CA2789038A1 (fr) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Reduction selective de variants alleliques
JP6006120B2 (ja) 2010-02-08 2016-10-12 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 対立遺伝子多様体の選択的低減
EP3173419A1 (fr) 2010-04-28 2017-05-31 Ionis Pharmaceuticals, Inc. Nucléosides modifiées, analogues correspondants et composés oligomères préparés à partir de ceux-ci
WO2011139699A2 (fr) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Nucléosides modifiés en 5' et composés oligomères préparés à partir de ceux-ci
WO2011139695A2 (fr) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Nucléosides 5' diphosphates modifiés et composés oligomères préparés à partir de ceux-ci
WO2011139911A2 (fr) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Arn simple brin à formulation lipidique
NZ603339A (en) 2010-04-29 2015-01-30 Isis Pharmaceuticals Inc Modulation of transthyretin expression
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
KR20180105730A (ko) 2010-07-19 2018-09-28 아이오니스 파마수티컬즈, 인코포레이티드 근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
JP5577506B2 (ja) 2010-09-14 2014-08-27 ソーラテック コーポレイション 遠心式ポンプ装置
FR2967310B1 (fr) 2010-11-04 2013-08-02 Xap Moteur electromagnetique sans balai
AU2011329777B2 (en) 2010-11-17 2016-06-09 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
EP2673361B1 (fr) 2011-02-08 2016-04-13 Ionis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations
WO2012132850A1 (fr) 2011-03-28 2012-10-04 Ntn株式会社 Dispositif de rotation et d'entraînement, et dispositif de pompe centrifuge utilisant ce dispositif
MY163004A (en) 2011-04-01 2017-07-31 Ionis Pharmaceuticals Inc Modulation of signal transducer and activator of transcription 3 (stat3) expression
DE102011016336A1 (de) 2011-04-07 2012-10-11 Airbus Operations Gmbh Hochauftriebssystem für ein Luftfahrzeug
JP5951752B2 (ja) 2011-04-13 2016-07-13 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｐｔｐ１ｂ発現のアンチセンス調節
JP6042871B2 (ja) 2011-04-21 2016-12-14 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節
KR20190062511A (ko) 2011-04-27 2019-06-05 아이오니스 파마수티컬즈, 인코포레이티드 아포지방단백질 ｃｉｉｉ （ａｐｏｃｉｉｉ） 발현의 조정
WO2012170347A1 (fr) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Nucléosides bicycliques et composés oligomères préparés à partir de ceux-ci
AU2012267546B2 (en) 2011-06-10 2015-12-24 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
CA2839437A1 (fr) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression du recepteur 4 du facteur de croissance fibroblastique
EP2726153B1 (fr) 2011-06-29 2018-03-28 Ionis Pharmaceuticals, Inc. Procédés de modulation de l'expression de kallicréine (klkb1)
WO2013022967A1 (fr) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Composés oligomères à brèche comprenant des désoxyribonucléosides modifiés en 5' dans la brèche, et leurs utilisations
EP2751270B1 (fr) 2011-08-29 2018-08-22 Ionis Pharmaceuticals, Inc. Complexes oligomère-conjugué et leur utilisation
CN108410868A (zh) 2011-09-20 2018-08-17 Ionis制药公司 Gcgr表达的反义调节
MX350944B (es) 2011-10-25 2017-09-26 Ionis Pharmaceuticals Inc Modulación antisentido de la expresión de gccr.
HRP20191883T1 (hr) 2011-11-07 2019-12-27 Ionis Pharmaceuticals, Inc. Modulacija ekspresije tmprss6
WO2013096837A1 (fr) 2011-12-22 2013-06-27 Isis Pharmaceuticals, Inc. Procédés pour la modulation d'une expression d'un transcrit 1 d'adénocarcinome associé à la métastase (malat-1)
ES2842938T3 (es) 2012-01-11 2021-07-15 Ionis Pharmaceuticals Inc Composiciones y métodos para la modulación del empalme de IKBKAP
US20140378533A1 (en) 2012-02-08 2014-12-25 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
US8837096B2 (en) 2012-03-13 2014-09-16 Thoratec Corporation Fault monitor for fault tolerant implantable pump
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (fr) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Nucléosides tricycliques et composés oligomères préparés à partir de ceux-ci
EP2839006B1 (fr) 2012-04-20 2018-01-03 Ionis Pharmaceuticals, Inc. Composés oligomères comprenant des nucléotides bicycliques et utilisations de ceux-ci
US9518261B2 (en) 2012-05-22 2016-12-13 Ionis Pharmaceuticals, Inc. Modulation of enhancer RNA mediated gene expression
HRP20201426T1 (hr) 2012-05-24 2020-11-27 Ionis Pharmaceuticals, Inc. Postupci i pripravci za moduliranje ekspresije apolipoproteina (a)
DK2864479T3 (en) 2012-06-25 2018-10-22 Ionis Pharmaceuticals Inc MODULATION OF UBE3A-ATS EXPRESSION
WO2014018930A1 (fr) 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation de maladies associées au système rénine—angiotensine (ras) par l'angiotensinogène
KR102237882B1 (ko) 2012-08-15 2021-04-07 아이오니스 파마수티컬즈, 인코포레이티드 변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
EP2897633B1 (fr) 2012-09-18 2020-01-01 UTI Limited Partnership Traitement de la douleur par inhibition de la déubiquitinase usp5
WO2014059364A1 (fr) 2012-10-11 2014-04-17 Isis Pharmaceuticals, Inc. Procédés de traitement de la maladie de kennedy
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
EP4086347A3 (fr) 2012-10-12 2023-01-11 Ionis Pharmaceuticals, Inc. Composés antisens sélectifs et leurs utilisations
WO2014059341A2 (fr) 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Composés anti-sens et leurs utilisations
FI2906696T4 (fi) 2012-10-15 2023-03-18 Menetelmiä c9orf72:n ilmentymisen moduloimiseksi
PL2920308T3 (pl) 2012-10-31 2019-06-28 Ionis Pharmaceuticals, Inc. Leczenie nowotworu
SG11201503821YA (en) 2012-11-15 2015-06-29 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
KR20150088305A (ko) 2012-11-26 2015-07-31 로슈 이노베이션 센터 코펜하겐 에이/에스 Fgfr3 발현의 조절을 위한 조성물 및 방법
US8968174B2 (en) 2013-01-16 2015-03-03 Thoratec Corporation Motor fault monitor for implantable blood pump
US9371826B2 (en) 2013-01-24 2016-06-21 Thoratec Corporation Impeller position compensation using field oriented control
RU2649367C2 (ru) 2013-01-30 2018-04-02 Ф. Хоффманн-Ля Рош Аг Конъюгаты углевода и lna-олигонуклеотида
WO2014118272A1 (fr) 2013-01-30 2014-08-07 Santaris Pharma A/S Conjugués glucidiques d'oligonucléotides antimir-22
ES2817050T3 (es) 2013-02-04 2021-04-06 Ionis Pharmaceuticals Inc Compuestos antisentido selectivos y usos de los mismos
CA3170716A1 (fr) 2013-02-14 2014-08-21 Ionis Pharmaceuticals, Inc. Modulation de l'expression de l'apolipoproteine c-iii (apociii) chez les populations presentant un deficit en lipoproteine lipase (lpld)
US9556873B2 (en) 2013-02-27 2017-01-31 Tc1 Llc Startup sequence for centrifugal pump with levitated impeller
CN105143470B (zh) 2013-02-28 2020-06-09 德克萨斯大学系统董事会 用于将癌症分类为易感于tmepai定向疗法以及治疗所述癌症的方法
DE102013102194A1 (de) * 2013-03-06 2014-09-11 Werner Eck Antriebseinrichtung für ein sich in einem Fluid bewegendes Fahrzeug
ES2807379T3 (es) 2013-03-14 2021-02-22 Ionis Pharmaceuticals Inc Composiciones y métodos para regular la expresión de Tau
US10052420B2 (en) 2013-04-30 2018-08-21 Tc1 Llc Heart beat identification and pump speed synchronization
KR102482890B1 (ko) 2013-05-01 2022-12-30 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법
AU2014284152B2 (en) 2013-06-21 2020-01-23 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
EP3011026B1 (fr) 2013-06-21 2019-12-18 Ionis Pharmaceuticals, Inc. Composés et méthodes de modulation de l'expression de l'alipoprotéine c-iii pour améliorer le profil diabétique
DK3013959T3 (da) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As Antisense-oligomerer og konjugater målrettet pcsk9
EP3730614A3 (fr) 2013-07-02 2020-12-30 Ionis Pharmaceuticals, Inc. Modulateurs de récepteur d'hormone de croissance
TW202246503A (zh) 2013-07-19 2022-12-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2015017675A2 (fr) 2013-07-31 2015-02-05 Isis Pharmaceuticals, Inc. Procédés et composés utiles dans des pathologies associées à un nombre plus grand de répétitions
WO2015021432A1 (fr) 2013-08-08 2015-02-12 The Scripps Research Institute Procédé d'étiquetage enzymatique spécifique de site d'acides nucléiques in vitro par incorporation de nucléotides non naturels
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
EP3715457A3 (fr) 2013-08-28 2020-12-16 Ionis Pharmaceuticals, Inc. Modulation de l'expression de la prékallikréine (pkk)
EP3043827B1 (fr) 2013-09-13 2019-07-03 Ionis Pharmaceuticals, Inc. Modulateurs du facteur b du complément
US9943604B2 (en) 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
MY192689A (en) 2013-10-11 2022-09-01 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
US9239345B2 (en) 2013-11-20 2016-01-19 Woodward, Inc. Controlling a motor with two or more Hall sensors
DK3077510T3 (da) 2013-12-02 2020-06-08 Ionis Pharmaceuticals Inc Antisense-forbindelser og anvendelser deraf
MX383753B (es) 2013-12-24 2025-03-14 Ionis Pharmaceuticals Inc Modulación de la expresión similar a la angiopoyetina tipo 3.
US10988030B2 (en) 2014-09-26 2021-04-27 Francis Xavier Gentile Electric motor, generator and battery combination
WO2015143246A1 (fr) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Compositions permettant de moduler l'expression de l'ataxine 2
MY192634A (en) 2014-04-01 2022-08-29 Biogen Ma Inc Compositions for modulating sod-1 expression
US10513706B2 (en) 2014-04-09 2019-12-24 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
WO2015164693A1 (fr) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. COMPOSÉS OLIGOMÈRES COMPRENANT UN ACIDE NUCLÉIQUE À CONFORMATION CONTRAINTE α-β
WO2015168172A1 (fr) 2014-04-28 2015-11-05 Isis Pharmaceuticals, Inc. Composés oligomères modifiés par liaison
CN106232125B (zh) 2014-05-01 2020-10-16 Ionis制药公司 用于调节pkk表达的组合物和方法
US10098959B2 (en) 2014-05-01 2018-10-16 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
WO2015179693A1 (fr) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Composés antisens conjugués et leur utilisation
US9623161B2 (en) 2014-08-26 2017-04-18 Tc1 Llc Blood pump and method of suction detection
WO2016077704A1 (fr) 2014-11-14 2016-05-19 The Regents Of The University Of California Modulation de l'expression de la protéine angptl5
CN105634225B (zh) * 2014-11-26 2020-10-09 德昌电机(深圳)有限公司 直流无刷电机及使用其的电动助力转向系统
AU2015360794B2 (en) 2014-12-08 2021-07-08 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
WO2016100716A1 (fr) 2014-12-18 2016-06-23 Vasant Jadhav Composés reversirtm
CN104617827B (zh) * 2015-02-02 2017-05-31 东南大学 一种电动汽车用轴向磁场磁通切换永磁电机容错控制方法
WO2016130846A1 (fr) 2015-02-11 2016-08-18 Thoratec Corporation Identification de battement cardiaque et synchronisation de vitesse de pompe
EP3256185B1 (fr) 2015-02-12 2019-10-30 Tc1 Llc Système et procédé de commande de la position d'un rotor en lévitation
US10371152B2 (en) 2015-02-12 2019-08-06 Tc1 Llc Alternating pump gaps
WO2016130989A1 (fr) 2015-02-13 2016-08-18 Thoratec Corporation Mécanisme de suspension de rotor pour pompe cardiaque
BR112017017178A2 (pt) 2015-02-26 2018-04-03 Ionis Pharmaceuticals Inc moduladores específicos de alelo de rodopsina de p23h
EP3265564B1 (fr) 2015-03-03 2022-01-26 Ionis Pharmaceuticals, Inc. Méthodes de modulation de l'expression de mecp2
WO2016141236A1 (fr) 2015-03-03 2016-09-09 Ionis Pharmaceuticals, Inc. Compositions permettant de moduler l'expression de mecp2
CA2990699A1 (fr) 2015-06-29 2017-01-05 Ionis Pharmaceuticals, Inc. Arn crispr modifie et arn crispr simple modifie et utilisations correspondantes
PE20180800A1 (es) 2015-07-10 2018-05-09 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
CA3205381A1 (fr) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Conjugues constitues d'une entite unique a cibles multiples
EP3349802B1 (fr) 2015-09-14 2021-08-04 The Board of Regents of the University of Texas System Dendrimères lipocationiques et leurs utilisations
TW201723176A (zh) 2015-09-24 2017-07-01 Ｉｏｎｉｓ製藥公司 Ｋｒａｓ表現之調節劑
US10117983B2 (en) 2015-11-16 2018-11-06 Tc1 Llc Pressure/flow characteristic modification of a centrifugal pump in a ventricular assist device
US11761007B2 (en) 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
US10562849B2 (en) 2016-05-16 2020-02-18 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
DK3475295T3 (da) 2016-06-24 2022-10-24 Scripps Research Inst Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
US12409756B2 (en) 2017-04-05 2025-09-09 H55 Sa Aircraft monitoring system and method for electric or hybrid aircrafts
US10854866B2 (en) 2019-04-08 2020-12-01 H55 Sa Power supply storage and fire management in electrically-driven aircraft
US11063323B2 (en) 2019-01-23 2021-07-13 H55 Sa Battery module for electrically-driven aircraft
US11148819B2 (en) 2019-01-23 2021-10-19 H55 Sa Battery module for electrically-driven aircraft
US11065979B1 (en) 2017-04-05 2021-07-20 H55 Sa Aircraft monitoring system and method for electric or hybrid aircrafts
US10479223B2 (en) 2018-01-25 2019-11-19 H55 Sa Construction and operation of electric or hybrid aircraft
US20200181220A1 (en) 2017-08-03 2020-06-11 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
TW202442671A (zh) 2018-02-26 2024-11-01 美商欣爍克斯公司 Il-15結合物及其用途
SG11202010910QA (en) 2018-05-07 2020-12-30 Alnylam Pharmaceuticals Inc Extrahepatic delivery
CA3114396A1 (fr) 2018-09-28 2020-04-02 Alnylam Pharmaceuticals, Inc. Compositions d'arni de la transthyretine (ttr) et leurs procedes d'utilisation pour traiter ou prevenir des maladies oculaires associees a la ttr
US20200246467A1 (en) 2019-02-06 2020-08-06 Synthorx, Inc. Il-2 conjugates and methods of use thereof
CN120290561A (zh) 2019-03-29 2025-07-11 田边三菱制药株式会社 用于调节dux4的表达的化合物、方法和医药组合物
CA3138915A1 (fr) 2019-05-17 2020-11-26 Alnylam Pharmaceuticals, Inc. Administration orale d'oligonucleotides
EP4013454A1 (fr) 2019-08-15 2022-06-22 Synthorx, Inc. Polythérapies immuno-oncologiques avec des conjugués d'il-2
CN114555632A (zh) 2019-08-23 2022-05-27 新索思股份有限公司 Il-15缀合物及其用途
CA3150082A1 (fr) 2019-09-10 2021-03-18 Jerod PTACIN Conjugues d'il-2 et methodes d'utilisation pour traiter des maladies auto-immunes
AU2020380275A1 (en) 2019-11-04 2022-04-14 Synthorx, Inc. Interleukin 10 conjugates and uses thereof
EP4055166A2 (fr) 2019-11-06 2022-09-14 Alnylam Pharmaceuticals, Inc. Administration extra-hépatique
EP4055165A1 (fr) 2019-11-06 2022-09-14 Alnylam Pharmaceuticals, Inc. Composition d'arni de la transthyrétine (ttr) et ses procédés d'utilisation pour le traitement ou la prévention de maladies oculaires associées à ttr
EP4151237A4 (fr) 2020-05-12 2024-08-14 Mitsubishi Tanabe Pharma Corporation Composé, méthode et composition pharmaceutique pour réguler l'expression d'ataxine-3
JP2023531509A (ja) 2020-06-25 2023-07-24 シンソークス， インコーポレイテッド Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法
WO2022011214A1 (fr) 2020-07-10 2022-01-13 Alnylam Pharmaceuticals, Inc. Parni circulaires
BR112023006364A2 (pt) 2020-10-09 2023-05-09 Synthorx Inc Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
EP4225375A1 (fr) 2020-10-09 2023-08-16 Synthorx, Inc. Thérapies immuno-oncologiques avec des conjugués d'il-2
WO2022087475A1 (fr) 2020-10-23 2022-04-28 The Scripps Research Institute Transcription inverse de polynucléotides comprenant des nucléotides non naturels
CR20230308A (es) 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
CA3207125A1 (fr) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. Promedicaments oligonucleotidiques a base de phosphate modifies par un disulfure cyclique
EP4271695A2 (fr) 2020-12-31 2023-11-08 Alnylam Pharmaceuticals, Inc. Promédicaments oligonucléotidiques à base de nucléosides modifiés en 2'
WO2022174102A1 (fr) 2021-02-12 2022-08-18 Synthorx, Inc. Polythérapie contre le cancer du poumon avec des conjugués d'il-2 et un anticorps anti-pd-1 ou un fragment de liaison à l'antigène de ce dernier
WO2022174101A1 (fr) 2021-02-12 2022-08-18 Synthorx, Inc. Polythérapie contre le cancer de la peau à l'aide de conjugués il-2 et de cemiplimab
MX2023011612A (es) 2021-03-31 2023-12-15 Entrada Therapeutics Inc Peptidos de penetracion celular ciclicos.
WO2022241408A1 (fr) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions et procédés de modulation de la distribution tissulaire d'agents thérapeutiques intracellulaires
US20250051393A1 (en) 2021-05-10 2025-02-13 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
WO2022240760A2 (fr) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions et procédés de modulation de l'épissage d'arnm
US11682997B2 (en) 2021-05-17 2023-06-20 Hitachi Astemo Americas, Inc. Rotary electric machine with selectable coil control
WO2022256534A1 (fr) 2021-06-03 2022-12-08 Synthorx, Inc. Polythérapie contre le cancer de la tête et du cou comprenant un conjugué d'il-2 et du pembrolizumab
IL309001A (en) 2021-06-23 2024-02-01 Entrada Therapeutics Inc Antisense compounds and methods for targeting CUG repeats
JP2024527584A (ja) 2021-07-09 2024-07-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド ＣＮＳ送達のためのＢｉｓ－ＲＮＡｉ化合物
WO2023003922A1 (fr) 2021-07-21 2023-01-26 Alnylam Pharmaceuticals, Inc. Compositions d'arni de gène cible associé à un trouble métabolique et leurs méthodes d'utilisation
IL311139A (en) 2021-09-01 2024-04-01 Entrada Therapeutics Inc Compounds and methods for skipping exon 44 in Duchenne muscular dystrophy
AU2022364838A1 (en) 2021-10-15 2024-04-11 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
WO2023086292A2 (fr) 2021-11-10 2023-05-19 University Of Rochester Agents thérapeutiques ciblant le gata4 pour le traitement de l'hypertrophie cardiaque
EP4430187A2 (fr) 2021-11-10 2024-09-18 University of Rochester Oligonucléotides antisens pour modifier l'expression de protéines
CA3241316A1 (fr) 2021-12-03 2023-06-08 Quralis Corporation Oligonucleotides antisens gapmeres avec des produits chimiques de squelette modifies
EP4452327A1 (fr) 2021-12-20 2024-10-30 Synthorx, Inc. Polythérapie contre le cancer de la tête et du cou comprenant un conjugué d'il-2 et du pembrolizumab
WO2023122750A1 (fr) 2021-12-23 2023-06-29 Synthorx, Inc. Polythérapie contre le cancer avec des conjugués d'il-2 et du cétuximab
US20250304957A1 (en) 2022-05-13 2025-10-02 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
JP2025522880A (ja) 2022-06-30 2025-07-17 アルナイラム ファーマシューティカルズ， インコーポレイテッド 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
WO2024039776A2 (fr) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Compositions d'arnsi universelles ne ciblant pas et procédés d'utilisation associés
WO2024050261A1 (fr) 2022-08-29 2024-03-07 University Of Rochester Agents thérapeutiques anti-fibrotiques à base d'oligonucléotides antisens
EP4594492A1 (fr) 2022-09-30 2025-08-06 Alnylam Pharmaceuticals, Inc. Agents arn double brin modifiés
WO2024136899A1 (fr) 2022-12-21 2024-06-27 Synthorx, Inc. Thérapie anticancéreuse avec des conjugués d'il-2 et des thérapies par récepteur antigénique chimérique
KR20250144467A (ko) 2023-02-09 2025-10-10 알닐람 파마슈티칼스 인코포레이티드 Reversir 분자 및 이의 사용 방법
TW202444349A (zh) 2023-03-20 2024-11-16 美商欣爍克斯公司 使用ｉｌ－２綴合物之癌症療法
AU2024254919A1 (en) 2023-04-12 2025-10-30 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery of double-stranded rna agents
WO2024238385A2 (fr) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Oligonucléotides à boucle simple brin
WO2025064660A2 (fr) 2023-09-21 2025-03-27 Alnylam Pharmaceuticals, Inc. Compositions d'arni de récepteur de type 1c de l'activine a (acvr1c) et leurs procédés d'utilisation
WO2025080939A1 (fr) 2023-10-13 2025-04-17 Ultragenyx Pharmaceutical, Inc. Compositions et méthodes de traitement d'états associés à des mutations de protéine matricielle oligomérique du cartilage (comp)
WO2025128853A2 (fr) 2023-12-13 2025-06-19 Ultragenyx Pharmaceutical Inc. Compositions et méthodes de traitement d'états pathologiques associés à une surexpression d'ube3a
WO2025158385A1 (fr) 2024-01-25 2025-07-31 Genzyme Corporation Il-2 pégylé pour supprimer une réponse immunitaire adaptative à une thérapie génique
WO2025207517A2 (fr) 2024-03-25 2025-10-02 Synthorx, Inc. Synthétases d'arnt synthétiques et cellules comprenant des molécules synthétiques pour la production de polypeptides
GB202404290D0 (en) 2024-03-26 2024-05-08 Senisca Ltd Novel oligoncleotides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809990A (en) * 1972-07-27 1974-05-07 Warner Electric Brake & Clutch Electric motor adapted for both stepping and continuous operation
US4434389A (en) * 1980-10-28 1984-02-28 Kollmorgen Technologies Corporation Motor with redundant windings
FR2541529A1 (fr) * 1983-02-18 1984-08-24 Sundstrand Corp Machine electromotrice a canaux multiples

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9414226A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108945485A (zh) * 2017-05-17 2018-12-07 通用电气公司 用于飞行器的推进系统

Also Published As

Publication number Publication date
WO1994014226A1 (fr) 1994-06-23
RU95114435A (ru) 1997-05-20
JPH08504559A (ja) 1996-05-14

Similar Documents

Publication Publication Date Title
WO1994014226A1 (fr) Systeme de moteur a tolerance de pannes
US5990643A (en) Sensorless commutation position detection for brushless D.C. motors
US5912522A (en) Permanent magnet direct current (PMDC) machine with integral reconfigurable winding control
US8084972B2 (en) Dual lane control of a permanent magnet brushless motor using non-trapezoidal commutation control
US5245238A (en) Axial gap dual permanent magnet generator
US5151637A (en) Deceleration apparatus for motor and drive circuit for use in motor deceleration apparatus or control apparatus for use in sewing machine
US4565956A (en) Fast-acting servo drive system
EP1588481A2 (fr) Optimisation de l'angle d'avance de phase pour commande de moteur sans balais
WO1992020135A1 (fr) Actuateur pour double generatrice a aimants permanents entrainee par couple
KR101290888B1 (ko) 전기 모터용 전류 공급 장치, 전기 모터 작동 방법
CN101490926A (zh) 电动机
WO2009110206A1 (fr) Dispositif de moteur sans balai et dispositif de commande
US5113824A (en) Adjusting device
US4454458A (en) Synchronous drive for brushless DC motor
US4401931A (en) Apparatus actuated by a pair of stepper motors with shared drive
US6646851B1 (en) Circuit arrangement for operating a solenoid actuator
EP0346764B1 (fr) Appareil de commande de moteur d'asservissement de papillon
CN105703590A (zh) 具有虚拟转子的磁阻马达
US6573672B2 (en) Fail passive servo controller
EP3346600B1 (fr) Actionneur à haute efficacité destiné à être utilisé dans un dispositif de commande d'élan
US4799002A (en) Method of driving a five-phase stepping motor
Adhul et al. Control electronics module for flow control valve using FPGA
US5783920A (en) Error signal control circuit for a phase-lock-loop sensorless motor controller
US5247217A (en) Safety system for a stepper-motor drive
WO2008103630A1 (fr) Réglage de commutation d'un moteur cc sans balai pour augmenter la vitesse de moteur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

17Q First examination report despatched

Effective date: 19951107

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19960301